# A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

> **NCT01262235** · PHASE1,PHASE2 · COMPLETED · sponsor: **Arbutus Biopharma Corporation** · enrollment: 68 (actual)

## Conditions studied

- Cancer
- Neuroendocrine Tumors
- NET
- Adrenocortical Carcinoma
- ACC

## Interventions

- **DRUG:** TKM-080301

## Key facts

- **NCT ID:** NCT01262235
- **Lead sponsor:** Arbutus Biopharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2015-07
- **Final completion:** 2015-08
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2019-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01262235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01262235, "A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01262235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*